Lacipil

Lacidipine, the active ingredient in Lacipil, is a calcium channel blocker presented as a tablet for oral use. It treats hypertension in adult patients.

GNH USA supplies Lacipil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacidipine is used to manage high blood pressure by targeting vascular smooth‑muscle tone.

Hypertension: lowers systolic and diastolic pressure, reducing the risk of cardiovascular events. Essential hypertension: provides sustained blood‑pressure control in patients requiring long‑term therapy. Secondary hypertension: may be employed when blood‑pressure elevation is due to identifiable causes, as part of a comprehensive treatment plan.

Lacidipine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: transient warmth and redness. - Peripheral edema: swelling of ankles or feet. - Dizziness or light‑headedness. - Tachycardia: increased heart rate. - Nausea or abdominal discomfort.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure. - Angioedema: swelling of face, lips, or throat. - Hepatic dysfunction: elevated liver enzymes. - Myocardial infarction: rare cardiac event. - Life‑threatening arrhythmias. - Anaphylactic reactions: severe allergic response.

Before initiating Lacidipine therapy, consider the following safety measures.

Monitor blood pressure: ensure target levels are achieved without excessive drop. Assess hepatic function: liver impairment may alter drug metabolism. Review concomitant antihypertensives: avoid additive hypotensive effects. Caution in elderly patients: increased sensitivity to blood‑pressure changes. Avoid abrupt discontinuation: taper dose to prevent rebound hypertension. Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Lacidipine can interact with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Other calcium‑channel blockers: additive vasodilatory effect. - Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increased plasma concentrations. - Grapefruit juice: may raise drug levels. - Concurrent antihypertensives causing profound hypotension. - Nitrates: risk of excessive blood‑pressure reduction.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance antihypertensive effect. - Beta‑blockers: monitor heart rate and blood pressure. - ACE inhibitors or ARBs: watch for additive hypotension. - NSAIDs: possible reduction in antihypertensive efficacy. - CYP3A4 inducers (e.g., rifampicin): may lower drug exposure.